Oxford, UK – 14 September 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that its subsidiary Oxford Biomedica Solutions LLC (“Oxford Biomedica Solutions”), a high-performing full-scope scope AAV manufacturing and innovation business, has signed an agreement with a new undisclosed, U.S. based, private biotechnology company. The agreement grants the partner access to Oxford Biomedica Solutions’ process and manufacturing platform, and “The Full Solution” service offering, with end-to-end capabilities for their pre-clinical gene therapy programmes.
Under the terms of the agreement, Oxford Biomedica Solutions will receive payments relating to the full scope of process development, from construct design through to toxicology manufacturing for the partner’s programmes.
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented:
“We are delighted to announce this new AAV partnership, and look forward to offering Oxford Biomedica Solutions’ full-scope platform to our new partner and supporting them with their construct design and product development needs. This agreement marks a very important step towards achieving our strategic objective of becoming a global viral vector leader across all key vector types, delivering life changing therapies to patients.”
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: firstname.lastname@example.org
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, VP, Corporate Affairs and Investor Relations
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: email@example.com
Mary-Jane Elliott / Matthew Neal / Matthew Cole
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com.